(Q46917660)

26 December 2017

title

Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells (English)

1 reference

26 December 2017

main subject

chronic myeloid leukemia

0 references

1 reference

1

1 reference

26 December 2017

Francesca Arruga

4

1 reference

26 December 2017

Valentina Rosso

Valentina Rosso

8

0 references

Angelo Guerrasio

Angelo Guerrasio

11

0 references

Riccardo Taulli

Riccardo Taulli

12

0 references

Giuseppe Saglio

Giuseppe Saglio

17

0 references

author name string

Daniela Cilloni

2

1 reference

26 December 2017

Francesca Messa

3

1 reference

26 December 2017

Ilaria Defilippi

5

1 reference

26 December 2017

Sonia Carturan

6

1 reference

26 December 2017

Renata Catalano

7

1 reference

26 December 2017

Annalisa Chiarenza

9

1 reference

26 December 2017

Chiara Pilatrino

10

1 reference

26 December 2017

Enrico Bracco

13

1 reference

26 December 2017

Marisa Pautasso

14

1 reference

26 December 2017

Daniela Baraban

15

1 reference

26 December 2017

Enrico Gottardi

16

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 March 2006

1 reference

26 December 2017

published in

Cancer

1 reference

26 December 2017

volume

106

1 reference

26 December 2017

issue

5

1 reference

26 December 2017

page(s)

1188-1196

1 reference

26 December 2017

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Imatinib mesylate--a new oral targeted therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Histone deacetylases as therapeutic targets in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Histone deacetylase is a target of valproic acid-mediated cellular differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21725

7 January 2021

Identifiers

DOI

10.1002/CNCR.21725

1 reference

26 December 2017

1 reference

26 December 2017